Home TOP100 Increase Decrease Search

mycentraloregon.com Traffic Analytics & Website Stats

Nikos Pekiaridis/NurPhoto via Getty Images(NEW YORK) -- Pfizer and BioNTech have launched a clinical trial on a vaccine targeting both COVID-19 and influenza, the companies announced Thursday. The phase 1 trial is being done in the United States with 180 participants between the ages of 18 and 64, with the first participant dosed this week, the companies said. The follow-up period for each participant will be six months. "By combining both indications in one vaccine approach, we aim to provide individuals with an efficient way to receive immunization against two severe respiratory diseases with evolving viruses that require vaccine adaptation," Dr. Ugur Sahin, CEO and co-founder of BioNTech, said in a statement. The combination vaccine is based on the currently available bivalent COVID-19 booster and a quadrivalent mRNA flu vaccine, which is designed to protect against four different flu viruses. The phase 1 trial will test for safety, immune response and optimal dose level of the combination vaccine, before moving on to larger trials. The data will also provide insight into the potential of mRNA vaccines to address more than one pathogen, Sahin said. Annaliesa Anderson, senior vice president and chief scientific officer of vaccine research and development for Pfizer, called this an "exciting step in our ongoing journey with BioNTech as we collectively look to transform the prevention of infectious diseases around the world." "Even with existing seasonal influenza vaccines, the burden of this virus is severe across the world causing thousands of deaths and hospitalizations every year," she said in a statement. Studies indicate​ COVID-19 vaccine efficacy fades over time, though it's not clear if every American will need an annual COVID-19 booster. As scientists continue to assess the need, several companies are at work on creating a single injection each fall that protects against both seasonal flu and COVID-19. In addition to Pfizer, pharmaceutical companies Moderna and Novavax have announced plans to work on a combo shot. Moderna said it anticipates starting clinical trials on a single-dose vaccine that combines a booster against COVID-19 and a booster against flu by the end of the year, with hopes of the vaccine being available for the 2023 season. "We believe this is a very large opportunity that is ahead of us, if we could bring to market a high efficacy pan-respiratory annual booster," Moderna COE Stéphane Bancel said during the Sept. 9 investor meeting. Last year, Novavax enrolled people in a Phase 1/2 study to evaluate the safety, tolerability and immune response of a combination vaccine using the company's seasonal influenza and COVID-19 vaccines. A phase 2 confirmation trial is expected to begin later this year, the company said in October. Copyright © 2022, ABC Audio. All rights reserved.
3.00

mycentraloregon.com is a domain having .com extension. mycentraloregon.com is a news and media website. mycentraloregon.com gets 41,528 traffic per month, the site is estimated to be worth $22,784.00. Over the last three months, mycentraloregon.com's global ranking has increased from 1,855,416 to 1,173,413. mycentraloregon.com's traffic has increased by 166.69% compared to last month, which is already a sign. Which countries sent the most traffic to mycentraloregon.com lately? Last month USA was the top country sending traffic to mycentraloregon.com. mycentraloregon.com's audience is 67.28% male and 32.72% female. The largest age group of visitors are 25 - 34 year olds.

Updated 1 year ago
Web Analysis
Traffic Report
Monthly Unique Visitors:

31,644

Monthly Pageviews:

41,528

Estimated Valuation
Income Per Day:

$ 47

Estimated Worth:

$ 22,784

Geography & Country Targeting
Countries Total Count:

14

Hot Country & Region:

USA

Search keywords & Backlinks
Keywords Total Count:

44

Backlinks Sites:

1

Global Ranks
Global Rank:

1,173,413

Country Rank:

9,961

Global Rank Change
Global Rank Change:

+1,303,588

Country Rank Change:

+307,816

  • Web Information
  • HTTP Information
  • Whois Information

Web Server Information

  • Hosted IP Address:

    34.206.231.65

  • Hosted Country:

    US

  • Location Latitude:

    39.043701171875

  • Location Longitude:

    -77.474197387695

Page Title of mycentraloregon.com

MyCentralOregon.com - Horizon Broadcasting Group, LLC | Bend, OR News and Information

Meta Description of mycentraloregon.com

Nikos Pekiaridis/NurPhoto via Getty Images(NEW YORK) -- Pfizer and BioNTech have launched a clinical trial on a vaccine targeting both COVID-19 and influenza, the companies announced Thursday. The phase 1 trial is being done in the United States with 180 participants between the ages of 18 and 64, with the first participant dosed this week, the companies said. The follow-up period for each participant will be six months. "By combining both indications in one vaccine approach, we aim to provide individuals with an efficient way to receive immunization against two severe respiratory diseases with evolving viruses that require vaccine adaptation," Dr. Ugur Sahin, CEO and co-founder of BioNTech, said in a statement. The combination vaccine is based on the currently available bivalent COVID-19 booster and a quadrivalent mRNA flu vaccine, which is designed to protect against four different flu viruses. The phase 1 trial will test for safety, immune response and optimal dose level of the combination vaccine, before moving on to larger trials. The data will also provide insight into the potential of mRNA vaccines to address more than one pathogen, Sahin said. Annaliesa Anderson, senior vice president and chief scientific officer of vaccine research and development for Pfizer, called this an "exciting step in our ongoing journey with BioNTech as we collectively look to transform the prevention of infectious diseases around the world." "Even with existing seasonal influenza vaccines, the burden of this virus is severe across the world causing thousands of deaths and hospitalizations every year," she said in a statement. Studies indicate​ COVID-19 vaccine efficacy fades over time, though it's not clear if every American will need an annual COVID-19 booster. As scientists continue to assess the need, several companies are at work on creating a single injection each fall that protects against both seasonal flu and COVID-19. In addition to Pfizer, pharmaceutical companies Moderna and Novavax have announced plans to work on a combo shot. Moderna said it anticipates starting clinical trials on a single-dose vaccine that combines a booster against COVID-19 and a booster against flu by the end of the year, with hopes of the vaccine being available for the 2023 season. "We believe this is a very large opportunity that is ahead of us, if we could bring to market a high efficacy pan-respiratory annual booster," Moderna COE Stéphane Bancel said during the Sept. 9 investor meeting. Last year, Novavax enrolled people in a Phase 1/2 study to evaluate the safety, tolerability and immune response of a combination vaccine using the company's seasonal influenza and COVID-19 vaccines. A phase 2 confirmation trial is expected to begin later this year, the company said in October. Copyright © 2022, ABC Audio. All rights reserved.

Meta Tags of mycentraloregon.com

Website Inpage Analysis

  • H1 Headings:

    0

  • H2 Headings:

    0

  • H3 Headings:

    4

  • H4 Headings:

    0

  • H5 Headings:

    34

  • H6 Headings:

    0

  • Total IFRAMEs:

    0

  • Total Images:

    56

  • Total Forms:

    1

  • Total Scripts:

    67

  • Google Adsense:

    pub-8348595418069829

  • Google Analytics:

    No Data

HTTP Header Analysis

HTTP/1.1 200 OK
Date: Fri, 04 Nov 2022 23:21:17 GMT
Content-Type: text/html; charset=UTF-8
Transfer-Encoding: chunked
Connection: keep-alive
Server: nginx
X-Frame-Options: SAMEORIGIN
Expires: Fri, 04 Nov 2022 23:21:22 GMT
Cache-Control: max-age=5
Pragma: no-cache
X-Redirect-By: WordPress
Location: https://www.mycentraloregon.com/
Content-Security-Policy: default-src * 'unsafe-inline' 'unsafe-eval' https
Strict-Transport-Security: max-age=63072000
X-Content-Type-Options: nosniff

Full WHOIS Lookup

Domain Name: MYCENTRALOREGON.COM
Registry Domain ID: 1052458811_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.godaddy.com
Registrar URL: http://www.godaddy.com
Updated Date: 2022-09-08T06:39:20Z
Creation Date: 2007-06-27T17:14:30Z
Registry Expiry Date: 2023-06-27T17:14:30Z
Registrar: GoDaddy.com, LLC
Registrar IANA ID: 146
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: 480-624-2505
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
Name Server: NS-1236.AWSDNS-26.ORG
Name Server: NS-1832.AWSDNS-37.CO.UK
Name Server: NS-62.AWSDNS-07.COM
Name Server: NS-913.AWSDNS-50.NET
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2022-11-23T13:19:37Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.
mycentraloregon.com

Similarly Ranked Websites

© 2022 YQQLM.Com. All Right Reserved.

Any other brand information used from us are the properties of their respective owners.